CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 3,700 enrolled
Drug / intervention
Groupother
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02676180
NCT02676180N/ACompleted

A Prospective Observational Study to Determine the Negative Predictive Value of UroMark to Rule Out the Presence of Bladder Cancer in Patients With Haematuria.

University College, London·observational·Posted Feb 8, 2016·Updated Dec 8, 2023

In Brief

An observational study evaluating Group for Bladder Cancer. Completed, enrolled 3,700 participants across 2 sites.

Detailed Summary

DETECT I is a prospective multicentre observational diagnostic study to assess the performance of the UroMark assay to rule out bladder cancer in patients with haematuria. The study will recruit consecutive patients attending haematuria clinics as well as patients referred to urology outpatient clinics for investigation of haematuria. Consenting patients will be provided with a urine sample collection kit and asked to provide a urine sample. An additional urine sample for control assay testing will be provided after the clinic attendance.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsBladder Cancer
CountriesUnited Kingdom
Collaborators--

Timeline

N/ACompletedFinished
20162017201820192020202120222023202420252026
First PostedFeb 8, 2016
Enrollment StartMar 30, 2016
Primary CompletionDec 1, 2017
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 10.4 years ago

Interventions

Groupother